OSVALDO LUIZ DA COSTA
3 resultados
Resultados de Busca
Agora exibindo 1 - 3 de 3
Resumo IPEN-doc 23458 Brazil radioactive sources production for cancer treatment2016 - ROSTELATO, MARIA E.; SOUZA, CARLA D.; ZEITUNI, CARLOS A.; MOURA, JOAO A.; MARQUES, JOSE R.O.; COSTA, OSVALDO L.; FEHER, ANSELMO; RODRIGUES, BRUNA T.; SOUZA, DAIANE C.B. de; PELEIAS JUNIOR, FERNANDO S.; SORGATTI, ANDERSON; MOSCA, RODRIGO; MOURA, EDUARDO S. de; ABREU, RODRIGO T.; SOUZA, RAQUEL V. DE; NOGUEIRA, BEATRIZ R.The modality, known as brachytherapy, was performed in Brazil by only a hand full of hospitals at an extremely high cost. For producing new sources, five major areas must be considered: 1) source production: nuclear activation and/or radiochemical reaction; 2) welding; 3) Quality control: leakage tests; 4) Dosimetry and metrology; 5) Operational procedures; 6) validation studies. To perform all steps, a multidisciplinary team works together to overcome difficulties. - Iridium-192 pellets: In Brazil there are 140 machines with pellets that replacement every 5 years. Our new production line has assembly, welding and quality control hot cells. - Iridium-192 wires: Produced since 1999. The wire is activated at IPENs IEA-R1 reactor for 30 hours with 5x1013 n/cm-2.s-1 neutron flux resulting in 192 mCi maximum activity. - Iridium-192 seed: New seed for ophthalmic cancer treatment. The irradiation device presented 90% activity homogeneity. We are still testing in-vivo. - Iodine-125 seeds: Largely used in low dose brachytherapy. I-125 binding yield achieved with our new reaction was 80%; Laser welding presented 70% efficiency. Approved in all leakage tests. - Other ongoing projects: Veterinary brachytherapy, Waste management, Radionecrosis healing with laser, calibrations sources production, linear accelerator calculations for hospitals, sources with polymeric matrix Our Iodine-125 seeds will be available in 2018. All other projects are advancing. We will continue to develop new products hoping to help the Brazilian population fight against cancer. For producing new sources, five major areas must be considered: 1) source production: nuclear activation and/or radiochemical reaction; 2) welding; 3) Quality control:eakage tests; 4) Dosimetry and metrology; 5) Operational procedures; 6) validation studies. To perform all steps, a multidisciplinary team works together to overcome difficultiesResumo IPEN-doc 23127 Experiment to access Iodine-125 leakage in different vials2017 - SOUZA, C.D. de; ROSTELATO, M.C.M.; ZEITUNI, C.; COSTA, O. da; RODRIGUES, B.T.; GONZALEZ, A.C.; MARQUES, J. de O.Purpose: There are several challenges when developing a laboratory to produce radioactive sources. From choosing a prototype to radiation safety, the task is enormous. During the past 15 years, our research group is developing a laboratory to produce iodine-125 seed. These seeds are placed inside the cancer and release radiation directly in the target. The whole production line is full of new process and innovations. Among those, a new chemical reaction that deposit iodine-125 onto silver (core) was developed. This paper presents a comparison between vials in order to access their capability to retain radioactive iodine. Also, the fixation percentage in a silver core was taken into account. This information will be used to select a vial to be implemented at the iodine-125 sources manufacture laboratory. Methods: Vials made with polymers and glass was tested. Iodine-125 were placed in the vials overnight at rt. Seven vials with different materials (glass, dark glass, and plastics) were evaluated. Results: The selected vial (borosilicate glass 1 mL total volume) loss 17.61% of iodine in 24 hours and presented the highest iodine intake. It was noticeable that the vial material influenced both iodine intake and iodine loss. The goal is to maximize the reaction yield to result in a less costly product. Conclusion: We have selected the best vial for our reaction in regards to leakage and yield.Resumo IPEN-doc 22300 Study and development of a iridium-192 seed for use in ophthalmic cancer2014 - ROSTELATO, M.; SOUZA, C. de; PELEIAS JUNIOR, F.S.; ZEITUNI, C.A.; MATTOS, F.R.; BENEGA, M.A.G.; MOURA, J.A.; FEHER, A.; COSTA, O.L.